Literature DB >> 8543077

Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage.

A P Moriarty1, I L McAllister, I J Constable.   

Abstract

Tissue plasminogen activator (tPA) (250 micrograms/ml) was used to facilitate removal of submacular thrombus in 15 patients. Following a three-port vitrectomy and subretinal tPA injection (0.1 ml) via a 30 gauge needle, blood was evacuated after enzymatic dissolution for 20 minutes. Two injections were required in some cases. Nine women and six men were treated (mean age 75.5 +/- 8.6 years). Duration of symptoms ranged from 2 days to 8 weeks. One case was due to a retinal macroaneurysm, the others to age-related macular degeneration. Vision improved in 13 patients and remained the same or deteriorated in 2 (mean follow-up 11 +/- 4.9 months). Well-defined subretinal neovascular membranes were identified in 2 patients and occult neovascularisation suspected in 2 others. A cataract developed in 1 case and retinal detachments in 2 others; all were treated successfully. The poor visual prognosis associated with submacular haemorrhage may be obviated by the use of the technique we describe.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543077     DOI: 10.1038/eye.1995.144

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  6 in total

1.  Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement.

Authors:  John T Thompson; Raymond N Sjaarda
Journal:  Trans Am Ophthalmol Soc       Date:  2005

2.  The end of submacular surgery for age-related macular degeneration? A meta-analysis.

Authors:  Christiane I Falkner; Harald Leitich; Florian Frommlet; Peter Bauer; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-05-04       Impact factor: 3.117

3.  Naïve subretinal haemorrhage due to neovascular age-related macular degeneration. pneumatic displacement, subretinal air, and tissue plasminogen activator: subretinal vs intravitreal aflibercept-the native study.

Authors:  Matias Iglicki; Marina Khoury; Javier Ignacio Melamud; Lucas Donato; Adiel Barak; Diego Jose Quispe; Dinah Zur; Anat Loewenstein
Journal:  Eye (Lond)       Date:  2022-08-29       Impact factor: 4.456

4.  Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.

Authors:  R P Singh; C Patel; J E Sears
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

5.  Intravitreal Expansile Gas and Bevacizumab Injection for Submacular Hemorrhage Due to Neovascular Age-related Macular Degeneration.

Authors:  Ramin Nourinia; Mohammad Hossein Jabbarpour Bonyadi; Hamid Ahmadieh
Journal:  J Ophthalmic Vis Res       Date:  2010-07

6.  Long-term clinical outcomes of submacular blood removal with isolated autologous retinal pigment epithelium-choroid patch graft transplantation in long-standing large-sized submacular hematomas: An Indian experience.

Authors:  Subhendu Kumar Boral; Deepak Agarwal; Arnab Das; Tushar Kanti Sinha
Journal:  Indian J Ophthalmol       Date:  2020-10       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.